High-dose melphalan and autologous bone marrow transplantation as consolidation in previously untreated myeloma.
暂无分享,去创建一个
T. Hickish | M. Nicolson | L. Paz-Ares | D. Cunningham | P. Selby | C. Viner | R. Powles | S. Milan | J. Treleavan | J. Malpas | Marianne Nicolson | David Cunningham | P. Selby
[1] M. Gore,et al. High-dose melphalan for multiple myeloma: long-term follow-up data. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] M. Gore,et al. Repeat administration of high dose melphalan in relapsed myeloma. , 1993, British Journal of Cancer.
[3] A. Freedman,et al. Monoclonal antibody-purged bone marrow transplantation therapy for multiple myeloma. , 1993, Blood.
[4] B. Mazières,et al. Maintenance treatment with recombinant alpha interferon after autologous bone marrow transplantation for aggressive myeloma in first remission after conventional induction chemotherapy. , 1991, Bone marrow transplantation.
[5] J. Trent,et al. Development and characterization of a melphalan-resistant human multiple myeloma cell line. , 1991, Cancer research.
[6] B. Barlogie,et al. Bone marrow transplantation in multiple myeloma. , 1991, Bone marrow transplantation.
[7] B. Barlogie,et al. Autologous bone marrow transplantation in multiple myeloma: identification of prognostic factors , 1990 .
[8] D. Cunningham,et al. Decrease in clonogenic tumour cells in bone marrow aspirates from multiple myeloma patients due to the incorporation of cyclophosphamide into treatment with vincristine, adriamycin and methyl prednisolone , 1990, Hematological oncology.
[9] B. Barlogie,et al. High-dose melphalan and granulocyte-macrophage colony-stimulating factor for refractory multiple myeloma. , 1990, Blood.
[10] F. Mandelli,et al. Maintenance treatment with recombinant interferon alfa-2b in patients with multiple myeloma responding to conventional induction chemotherapy. , 1990, The New England journal of medicine.
[11] M. Gore,et al. In vitro studies of ways to overcome resistance to VAMP‐high dose melphalan in the treatment of multiple myeloma , 1989, British journal of haematology.
[12] D. Bergsagel. Is aggressive chemotherapy more effective in the treatment of plasma cell myeloma? , 1989, European journal of cancer & clinical oncology.
[13] Y. Lévy,et al. Treatment of aggressive multiple myeloma by high-dose chemotherapy and total body irradiation followed by blood stem cells autologous graft. , 1989, Blood.
[14] B. Barlogie,et al. Prognostic factors with high-dose melphalan for refractory multiple myeloma [see comments] , 1988 .
[15] D. Bergsagel. Chemotherapy of myeloma: Drug combinations versus single agents, an overview, and comments on acute leukemia in myeloma , 1988, Hematological oncology.
[16] M. Slevin,et al. Multiple myeloma treated with high dose intravenous melphalan , 1987, British journal of haematology.
[17] J. Sporn,et al. Chemotherapy of previously untreated multiple myeloma patients: an analysis of recent treatment results. , 1986, Seminars in Oncology.
[18] T. Mcelwain,et al. HIGH-DOSE INTRAVENOUS MELPHALAN FOR PLASMA-CELL LEUKAEMIA AND MYELOMA , 1983, The Lancet.
[19] E. Gehan,et al. Prognostic factors in multiple myeloma , 1975, Cancer.
[20] S. Salmon,et al. A clinical staging system for multiple myeloma correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival , 1975, Cancer.
[21] David R. Cox,et al. Regression models and life tables (with discussion , 1972 .
[22] E. Kaplan,et al. Nonparametric Estimation from Incomplete Observations , 1958 .